Payment overview · 2025
General Payments
$172.64
8 reported records · 6 companies
Healthcare provider profile · identity verified
George A Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · PENSACOLA, FL · NPI 1861405862
Verified facts
What the public records show
CMS Open Payments records show George A Smith, MD received $172.64 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.20 | 43.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.10 | 19.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.14 | 11.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.11 | 9.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.41 | 8.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.68 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.64 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 375 | 135 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 110 |
| Tramadol Hcl | Tramadol Hcl | 287 | 46 |
| Losartan Potassium | Losartan Potassium | 203 | 63 |
| Lisinopril | Lisinopril | 185 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 70 |
| Metformin Hcl | Metformin Hcl | 179 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 49 |
| Omeprazole | Omeprazole | 167 | 61 |
| Gabapentin | Gabapentin | 147 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 46 |
| Furosemide | Furosemide | 128 | 44 |
| Potassium Chloride | Potassium Chloride | 112 | 39 |
| Farxiga | Dapagliflozin Propanediol | 103 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 40 |
| Famotidine | Famotidine | 95 | 30 |
| Ibuprofen | Ibuprofen | 95 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 26 |
| Alprazolam | Alprazolam | 91 | 12 |
| Montelukast Sodium | Montelukast Sodium | 82 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 29 |
| Simvastatin | Simvastatin | 77 | 27 |
| Trazodone Hcl | Trazodone Hcl | 77 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 31 |
| Meloxicam | Meloxicam | 73 | 16 |
| Carvedilol | Carvedilol | 70 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 18 |
| Ozempic | Semaglutide | 70 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 21 |
| Clonidine Hcl | Clonidine Hcl | 63 | 22 |
| Alendronate Sodium | Alendronate Sodium | 60 | 23 |
| Pregabalin | Pregabalin | 60 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 19 |
| Eliquis | Apixaban | 58 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 14 |
| Spironolactone | Spironolactone | 46 | 17 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Atenolol | Atenolol | 41 | 14 |
| Sertraline Hcl | Sertraline Hcl | 41 | 15 |
| Allopurinol | Allopurinol | 40 | 16 |
| Glimepiride | Glimepiride | 38 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 12 |
| Methocarbamol | Methocarbamol | 33 | 13 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 15 |
| Cephalexin | Cephalexin | 23 | 21 |
| Diazepam | Diazepam | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 14 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Prednisone | Prednisone | 16 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.64 · 8 records | ABBVIE INC. | Dexcom G6 Transmitter, LEQVIO, MAVYRET, MOUNJARO, QULIPTA, Repatha, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error